US 12,239,705 B2
Therapeutic mitigation of epithelial infection
Matthew G. Brewer, Rochester, NY (US); Lisa A. Beck, Rochester, NY (US); Brian M. Ward, Rochester, NY (US); and Benjamin L. Miller, Rochester, NY (US)
Assigned to University of Rochester, Rochester, NY (US)
Filed by University of Rochester, Rochester, NY (US)
Filed on Apr. 21, 2021, as Appl. No. 17/236,099.
Application 17/236,099 is a continuation in part of application No. PCT/US2019/056853, filed on Oct. 18, 2019.
Claims priority of provisional application 62/755,029, filed on Nov. 2, 2018.
Prior Publication US 2021/0268103 A1, Sep. 2, 2021
Int. Cl. A61K 39/285 (2006.01); A61K 31/519 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/285 (2013.01) [A61K 31/519 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); C07K 16/244 (2013.01); C07K 16/2866 (2013.01); A61K 2039/525 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method of preventing skin viral infection in a subject in need thereof, the method comprising administering an effective amount of a Janus kinase (JAK) inhibitor and a Th2 pathway antagonist to the subject,
wherein the JAK inhibitor is selected from the group consisting of pyridone 6, abrocitinib, and ruxolitinib, and
wherein the Th2 pathway antagonist is an antibody selected from the group consisting of dupilumab, tralokinumab, lebrikizumab, nemolizumab, etokimab, tezepelumab, mepolizumab, reslizumab, and benralizumab.